Merus is a privately-held Dutch biopharmaceutical company building a pipeline of innovative human therapeutic antibodies. By using its proprietary technology platforms that include novel transgenic mice (MeMo™) Merus aims to produce highly potent human antibody-based drugs for the treatment of cancer, infectious and inflammatory diseases, whether as full-length bispecific antibodies or as Oligoclonics™, which are mixtures of therapeutic human monoclonal antibodies produced by a single cell. 

Web: www.merus.nl